ORIC Share Price | Oric Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: What does Oric Pharmaceuticals, Inc. do?

Overview: Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.Financial Snapshot: Most recent Net Profit: -30 Million (Quarterly Results - Mar 2025) Market cap: USD 769.57 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.91 Return on Equity: -60.46% Price to Book: 3.50Contact Details: Address: 240 E. Grand Ave., 2nd Floor, SOUTH SAN FRANCISCO CA: 94080 Tel: 1 650 3885600 Fax: 1 302 6555049 Website: http://oricpharma.com/

Q: Is Oric Pharmaceuticals, Inc. technically bullish or bearish?

As of 24 October 2025, the technical trend for Oric Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands also indicate a bullish stance for both periods. Daily moving averages are bullish, supporting the overall positive trend. However, the KST is mildly bearish on both weekly and monthly charts, and the OBV shows a mildly bearish trend on the weekly but no trend on the monthly. Dow Theory indicates a mildly bullish stance on both time frames.In terms of performance, Oric Pharmaceuticals has outperformed the S&P 500 across multiple periods, with a year-to-date return of 62.33% compared to the S&P 500's 15.47%, and a one-year return of 55.21% versus 16.90%. Overall, the current technical stance is bullish with moderate strength, driven primarily by the positive MACD and moving averages.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

483.15 k

Shareholding (Dec 2025)

FII

16.25%

Held by 80 FIIs

DII

13.25%

Held by 40 DIIs

Promoter

43.53%

How big is Oric Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Oric Pharmaceuticals, Inc. has a market capitalization of 769.57 million and reported net sales of 0.00 million with a net profit of -132.86 million over the latest four quarters. The balance sheet as of Dec'24 shows shareholder's funds of 243.12 million and total assets of 276.73 million.

View full answer

What does Oric Pharmaceuticals, Inc. do?

22-Jun-2025

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on overcoming cancer resistance, with a market cap of approximately $769.57 million and a recent net profit of -$30 million. The company does not currently pay dividends and has a negative return on equity of -60.46%.

View full answer

Who are in the management team of Oric Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Oric Pharmaceuticals, Inc. includes Dr. Richard Heyman (Independent Chairman), Dr. Jacob Chacko (CEO and Director), Dr. Lori Kunkel (Director), and Mr. Peter Svennilson (Board member).

View full answer

Is Oric Pharmaceuticals, Inc. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Oric Pharmaceuticals, Inc. shows a bullish technical trend supported by positive MACD and moving averages, despite some mild bearish signals from KST and OBV, and has significantly outperformed the S&P 500 year-to-date.

View full answer

Compare Oric Pharmaceuticals, Inc. with Similar Stocks

Arbutus Biopharma Corp.Coherus BioSciences, Inc.Nurix Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,226 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.70

Return on Equity

-33.24%

Price to Book

3.01

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-31 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

31.67%

6 Months

6.12%

1 Year

50.61%

2 Years

-20.2%

3 Years

111.03%

4 Years

125.61%

5 Years

-53.98%

Oric Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-193.30%

EBIT to Interest (avg)

-98.44

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.91

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.01

EV to EBIT

-6.37

EV to EBITDA

-6.42

EV to Capital Employed

7.66

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-120.27%

ROE (Latest)

-33.24%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 44 Schemes (26.97%)

Foreign Institutions

Held by 80 Foreign Institutions (16.25%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 15.98% vs -28.27% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-34.20",
          "val2": "-39.30",
          "chgp": "12.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-30.50",
          "val2": "-36.30",
          "chgp": "15.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -1.33% vs -26.91% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-141.80",
          "val2": "-141.80",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-129.50",
          "val2": "-127.80",
          "chgp": "-1.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-34.20

-39.30

12.98%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-30.50

-36.30

15.98%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 15.98% vs -28.27% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-141.80

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-129.50

-127.80

-1.33%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -1.33% vs -26.91% in Dec 2024

All Annual Results

Company CV

About Oric Pharmaceuticals, Inc.

Oric Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by overcoming resistance in cancer. The Company is focused on developing a diverse pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its experience within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its lead product candidate is ORIC-101. The Company’s ORIC-101 is a potent and selective small-molecule antagonist of the glucocorticoid receptor (GR), which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. The Company’s second product candidate, ORIC-533, is an orally bioavailable, small-molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy-and immunotherapy-based treatment regimens. Its third product candidate, ORIC-944, being developed for prostate cancer.

Company Coordinates

Company Details

240 E. Grand Ave., 2nd Floor , SOUTH SAN FRANCISCO CA : 94080

Tel: 1 650 3885600

http://oricpharma.com/

Registrar Details